Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hammond

Showing results (541-550 of 711) with videos related to

Pageof 72
Sort By:
The American Journal of Clinical Nutrition|August 30, 2022
An agent-based model of child sugar-sweetened beverage consumption: implications for policies and practicesMatt Kasman, Ross A Hammond, Rob Purcell, et al.
Annals of Epidemiology|September 8, 2012
The PhenX Toolkit pregnancy and birth collectionsNedra S Whitehead, Jane A Hammond, Michelle A Williams, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 26, 2011
Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lipMichael Lock, Jeffrey Q Cao, David P D'Souza, et al.
BMJ Open|August 8, 2015
Protocol for a randomised controlled trial for Reducing Arthritis Fatigue by clinical Teams (RAFT) using cognitive-behavioural approachesS Hewlett, N Ambler, C Almeida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, John Kuhn, Garry Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trialMalcolm Ranson, Lisa A Hammond, David Ferry, et al.
Journal of the American Society of Nephrology : JASN|August 3, 2013
Soluble CR1 therapy improves complement regulation in C3 glomerulopathyYuzhou Zhang, Carla M Nester, Danniele G Holanda, et al.
American Journal of Preventive Medicine|December 12, 2022
Understanding Misimplementation in U.S. State Health Departments: An Agent-Based ModelMatt Kasman, Ross A Hammond, Rob Purcell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.
Mbio|March 14, 2019
Novel Intersubunit Interaction Critical for HIV-1 Core Assembly Defines a Potentially Targetable Inhibitor Binding PocketPierrick Craveur, Anna T Gres, Karen A Kirby, et al.
Pageof 72

Showing results (541-550 of 711) with videos related to

Sort By:
Pageof 72
The American Journal of Clinical Nutrition|August 30, 2022
An agent-based model of child sugar-sweetened beverage consumption: implications for policies and practicesMatt Kasman, Ross A Hammond, Rob Purcell, et al.
Annals of Epidemiology|September 8, 2012
The PhenX Toolkit pregnancy and birth collectionsNedra S Whitehead, Jane A Hammond, Michelle A Williams, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 26, 2011
Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lipMichael Lock, Jeffrey Q Cao, David P D'Souza, et al.
BMJ Open|August 8, 2015
Protocol for a randomised controlled trial for Reducing Arthritis Fatigue by clinical Teams (RAFT) using cognitive-behavioural approachesS Hewlett, N Ambler, C Almeida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, John Kuhn, Garry Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trialMalcolm Ranson, Lisa A Hammond, David Ferry, et al.
Journal of the American Society of Nephrology : JASN|August 3, 2013
Soluble CR1 therapy improves complement regulation in C3 glomerulopathyYuzhou Zhang, Carla M Nester, Danniele G Holanda, et al.
American Journal of Preventive Medicine|December 12, 2022
Understanding Misimplementation in U.S. State Health Departments: An Agent-Based ModelMatt Kasman, Ross A Hammond, Rob Purcell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.
Mbio|March 14, 2019
Novel Intersubunit Interaction Critical for HIV-1 Core Assembly Defines a Potentially Targetable Inhibitor Binding PocketPierrick Craveur, Anna T Gres, Karen A Kirby, et al.
Pageof 72